Bayer Shares Fall as Weak 2026 Profit Outlook Overshadows Strong Q4 Results
Bayer reported better-than-expected fourth-quarter earnings, supported mainly by strong performance in its Crop Science division. However, the company’s profit guidance for 2026 disappointed investors, causing its shares to drop about 3.5% after the announcement.
Bayer Q4 Sales Beat Market Expectations
The German life sciences group reported fourth-quarter sales of €11.44 billion, slightly above the €11.34 billion expected by analysts. On an organic basis, revenue increased 2.9%, driven by a 3.7% rise in sales volumes, although pricing declined 0.8%.
Bayer’s adjusted EBITDA reached €1.97 billion, exceeding the €1.91 billion analyst consensus. Despite the earnings beat, the company’s adjusted EBITDA margin declined to 17.2%, representing a drop of 280 basis points compared with the previous year.
Crop Science Drives Earnings Beat
Among Bayer’s divisions, Crop Science delivered the strongest performance during the quarter.
The segment reported sales of €5.40 billion, surpassing the €5.19 billion expected by analysts. Adjusted EBITDA in the division came in at €766 million, also beating the €740 million consensus forecast.
Analysts noted that the strong performance in Crop Science was the primary factor behind the company’s earnings outperformance.
Mixed Performance Across Other Divisions
Bayer’s Pharmaceuticals division generated €4.48 billion in sales, slightly below the €4.55 billion expected by analysts. However, adjusted EBITDA reached €1.04 billion, outperforming the €994 million consensus estimate.
The Consumer Health segment continued to lag behind expectations. Sales in the division totaled €1.46 billion, missing the €1.50 billion forecast, while adjusted EBITDA of €305 million also fell short of the €333 million expected by analysts.
According to Jefferies analyst Chris Counihan, the positive surprise in the quarter was mainly driven by the strong results in the Crop Science business.
Bayer 2026 Outlook Disappoints Investors
Looking ahead, Bayer projected currency-adjusted net sales between €43.7 billion and €45.7 billion for 2026.
The company expects EBITDA before special items to range between €9.1 billion and €9.6 billion. However, the upper end of this forecast came in slightly below market expectations of €9.67 billion, according to analyst consensus published on Bayer’s website.
Bayer also guided core earnings per share between €4.00 and €4.50, which fell short of the €4.72 consensus estimate.
Cash Flow and Debt Outlook
The company expects free cash flow to range between negative €2.5 billion and negative €1.5 billion, reflecting continued financial pressure.
Bayer also projected net financial debt between €32 billion and €33 billion, highlighting ongoing balance sheet challenges despite stronger quarterly earnings.
